 SOUTH PLAINFIELD, N.J., Feb. 4, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of TranslarnaTM ataluren in patients with nonsense mutation Duchenne muscular dystrophy. The... 